Osilodrostat and Treatment of Cushing's Disease

November 2, 2020
Patrick Campbell

Georgiana Dobri, MD, a neuroendocrinologist from Weill Cornell Medicine, discusses the approval of osilodrostat and management of Cushing's disease in 2020.

This episode of the Endocrine Outlook podcast features an interview with Georgiana Dobri, MD, a board-certified neuroendocrinologist of Weill Cornell Medicine. In the interview, Dobri offers perspective on Cushing’s Disease and the role of osilodrostat (Isturisa) in treatment of the rare disease. Approved earlier this year for patients for whom pituitary surgery is not an option or has not been curative, osilodrostat has the ability to transform treatment algorithms, as well as the lives of patients.